NeuroVive Pharmaceutical AB (publ): report from EGM
Today, 31 March 2016, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. All resolutions were passed with the required majority.Approval of the board of directors’ resolution to issue shares and warrants with preferential rights for existing shareholdersThe EGM resolved to approve the board of directors’ resolution as of 28 February 2016 to issue not more than 17,984,960 shares and to issue not more than 2,248,120 warrants of series 2016/2017:1 and not more than 2,248,120 warrants of series